Curanex Pharmaceuticals Inc
CURX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CURX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CURX
Curanex Pharmaceuticals Inc (CURX) is a developmental-stage pharmaceutical company focused on botanical drugs for inflammatory diseases, with its lead candidate Phyto-N targeting ulcerative colitis and an IND submission planned for Q4 2026.
Key risk: Cash runway uncertainty
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 1 clinical trial for Curanex Pharmaceuticals Inc.
Curanex Pharmaceuticals Inc (CURX) is a developmental-stage pharmaceutical company focused on botanical drugs for inflammatory diseases, with its lead candidate Phyto-N targeting ulcerative colitis and an IND submission planned for Q4 2026.
- Curanex is a developmental-stage company dedicated to discovering and commercializing botanical drugs for inflammatory diseases, with a mission to address unmet medical needs [sec_mda · as of 2026-08-14].
- As of June 30, 2026, the company had cash and equivalents of $2.9M, an accumulated deficit of $11.3M, and reported a net loss of $6.4M for the first half of 2026 [sec_mda · as of 2026-08-14].
- The lead product candidate, Phyto-N, is being developed for ulcerative colitis, with an IND submission targeted for Q4 2026 and a Phase I trial planned thereafter [sec_mda · as of 2026-08-14].
- The company completed an IPO in August 2025, raising net proceeds of approximately $13.2M, plus an additional $2.1M from the underwriters' over-allotment option in September 2025 [sec_mda · as of 2025-11-17].
- Curanex has not generated any revenue since inception and expects R&D expenditures to increase substantially as it advances toward clinical trials [sec_mda · as of 2026-08-14].
What works
- The company has a clear near-term catalyst: an IND submission for Phyto-N in ulcerative colitis targeted for Q4 2026, which could initiate clinical development [sec_mda · as of 2026-08-14].
- Curanex successfully completed an IPO in 2025, raising approximately $15.3 million in net proceeds, providing capital to fund operations and development activities [sec_mda · as of 2025-11-17].
- The company is pursuing a precision medicine approach with translational research on biomarkers and patient stratification, which may optimize clinical trial design [sec_mda · as of 2026-03-30].
What to weigh
- Curanex has no revenue, a history of net losses, and an accumulated deficit of $11.3M as of June 30, 2026, with cash burn expected to increase as clinical activities ramp up [sec_mda · as of 2026-08-14].
- The company's cash position of $2.9M as of June 30, 2026, may be insufficient to fund the planned IND submission and Phase I trial without additional financing [sec_mda · as of 2026-08-14].
- There is no guarantee of regulatory approval for Phyto-N; the process is lengthy, expensive, and uncertain, and the company may need to delay or reduce programs if capital is not raised [sec_mda · as of 2026-03-30].
- Issuance of additional equity would dilute existing stockholders, and debt financing may involve restrictive covenants [sec_mda · as of 2026-08-14].
From the filings
Quoted directly from source documents.
The company is developmental-stage and focused on botanical drugs for inflammatory diseases.
“a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases.”
SEC MD&A · August 14, 2026
Cash and equivalents as of June 30, 2026, were $2.9M with an accumulated deficit of $11.3M.
“As of June 30, 2026, we had cash and cash equivalents of $2,938,463 and an accumulated deficit of $11,288,753.”
SEC MD&A · August 14, 2026
The company plans to submit an IND for Phyto-N in Q4 2026 and initiate a Phase I trial.
“We further expect our research and development expenditures to increase in connection with our targeted Investigational New Drug application submission in the fourth quarter of 2026 and the initiation of a Phase I clinical trial thereafter.”
SEC MD&A · August 14, 2026
The company has not generated any revenue since inception and has incurred recurring net losses.
“We have not generated any revenue since inception and have incurred recurring net losses and negative cash flows from operations.”
SEC MD&A · August 14, 2026
Risks & what to watch (4)›
Key risks
- Cash runway uncertainty — Cash of $2.9M as of June 30, 2026, may not be sufficient to fund planned IND and Phase I trial without additional capital [sec_mda · as of 2026-08-14].
- No revenue or approved products — Company has no revenue, an accumulated deficit of $11.3M, and expects R&D spending to increase substantially [sec_mda · as of 2026-08-14].
- Regulatory and clinical risk — No guarantee of regulatory approval for Phyto-N; process is lengthy, expensive, and uncertain [sec_mda · as of 2026-03-30].
- Dilution from future financing — Additional equity financing would dilute existing stockholders; debt may involve restrictive covenants [sec_mda · as of 2026-08-14].
What to watch
- IND submission for Phyto-N in ulcerative colitis, targeted for Q4 2026 [sec_mda · as of 2026-08-14].
- Initiation of Phase I clinical trial for Phyto-N, expected after IND submission [sec_mda · as of 2026-08-14].
- Cash burn rate and any additional financing activities, as cash position is limited [sec_mda · as of 2026-08-14].
- Progress on manufacturing, toxicology, and patent milestones for Phyto-N [news · published 2026-03-30].
Sources: News · SEC MD&A · Generated August 25, 2026 · How we verify sources →
Run Curanex Pharmaceuticals Inc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Curanex Pharmaceuticals Inc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
9.7 months
D/E 0.06 · 0% dilution
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
8
Total value held
$168K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 111,130 | $57K |
| two sigma securities, llc | 56,651 | $29K |
| xtx topco ltd | 51,289 | $26K |
| citadel advisors llc | 50,559 | $26K |
| two sigma investments, lp | 20,254 | $10K |
| citigroup inc | 19,332 | $10K |
| jump financial, llc | 10,551 | $5K |
| ubs group ag | 7,995 | $4K |
Short Interest
as of May 20, 2026- % of float
- 0.7%
- Days to cover
- 0.0
- Shares short
- 137,290
- Daily short volume (Jun 16, 2026)
- 25.0%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CURX short interestFrequently asked questions
What is the AI investment thesis for Curanex Pharmaceuticals Inc?
Curanex Pharmaceuticals Inc (CURX) is a developmental-stage pharmaceutical company focused on botanical drugs for inflammatory diseases, with its lead candidate Phyto-N targeting ulcerative colitis and an IND submission planned for Q4 2026.
What is Curanex Pharmaceuticals Inc's lead drug candidate?
Curanex Pharmaceuticals Inc's most advanced tracked candidate is Phyto-N (Preclinical) for gout.
Who is the CEO of Curanex Pharmaceuticals Inc?
Mr. Jun Liu is the chief executive officer of Curanex Pharmaceuticals Inc (CURX).
Where is Curanex Pharmaceuticals Inc headquartered?
Curanex Pharmaceuticals Inc (CURX) is headquartered in Jericho, NY, United States.
What therapeutic areas does Curanex Pharmaceuticals Inc focus on?
Curanex Pharmaceuticals Inc develops therapies across Cardiovascular, Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.